Radiosensitizing effects of gefitinib at different administration times in vitro

Cancer Science

Volumn 100, Issue 8, 2009, Pages 1520-1525

  Zhuang, Hong Qing ^a   Sun, Jian ^a   Yuan, Zhi Yong ^a   Wang, Jun ^a   Zhao, Lu Jun ^a   Wang, Ping ^a   Ren, Xiu Bao ^a   Wang, Chang Li ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; GEFITINIB; PROTEIN BAX; PROTEIN BCL 2; PROTEIN CDC25C; PROTEIN P21; RAD51 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL KILLING; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA REPAIR; DRUG EFFICACY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION EXPOSURE; RADIATION RESPONSE; RADIOSENSITIZATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; COLONY-FORMING UNITS ASSAY; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; X-RAYS;

EID: 67650689632     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01190.x     Document Type: Article

References (47)

1. Masui H, Kawamoto T, Sato JD et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44: 1002-7.
2. Yaish P, Gazit A, Gilon C et al. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988; 242: 933-5.
3. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer 2004; 4: 361-70.
4. Jose B. Epidermal growth factor receptor pathway inhibitors. Update on Cancer Therapeut 2006; 1: 299-310.
5. Fortunato C, Giampaolo T. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-74.
6. Fortunato C, Giampaolo T. Novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-70.
7. Zhu ZP. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: Status and perspectives. Acta Pharmacol Sin 2007; 28: 1476-93.
8. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11: 689-708.
9. Olivier D, Alexandre B, Gerard M et al. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors similarities differences. Crit Rev Oncol Hemato 2007; 62: 53-61.
10. Kris MG, Natale RB, Herbst RS. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003; 290: 2149-58.
11. Fukuoka M, Yano S, Giaccone G. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21: 2237-46.
12. Bonner JA, Harari PM, Giralt J. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
13. Cunningham D, Humblet Y, Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
14. Haas-Kogan DA, Prados MD, Tihan T. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005; 97: 880-7.
15. Mellinghoff IK, Wang MY, Vivanco I. Molecular determinants of the response of glioblastomas to EGFR kinaseinhibitors. N Engl J Med 2005; 353: 2012-24.
16. Barber TD, Vogelstein B, Kinzler KW. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004; 351: 2270-883.
17. Marie Y, Carpentier AF, Omuro AM. EGFR tyrosine kinase domain mutations in human gliomas. Neurology 2005; 64: 1444-5.
18. Harari PM. Promising new advances in head and neck radiotherapy. Ann Oncol 2005;16:13-19.
19. Crombet T, Osorio M, Cruz T et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22: 1646-54.
20. Wang RR, Wang SX, Zhao C et al. Phase II clinical trial of h-R3 combined radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Chin J Cancer 2007; 26: 874-9.
21. Huang XD, Yi JL, Gao L et al. Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Chin J Onco 2007; 29: 197-202.
22. James AB, Paul MH, Abdollahi A et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. Engl J Med 2006; 354: 567-78.
23. Prakash C, Shyhmin H, Geetha V et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005; 65: 3328-35.
24. Jaramillo ML, Banville M, Collins C et al. Differential sensitivity of A549 non-small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors. Cancer Biol Ther 2008; 7: 557-68.
25. Nyati MK, Morgan MA, Feng FY et al. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006; 6: 876-85.
26. Baumann M, Krause M, Dikomey E et al. EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms. Radiother Oncol 2007; 83: 238-48.
27. Zips D, Krause M, Yaromina A et al. Epidermal growth factor receptor inhibitors for radiotherapy: Biological rationale and preclinical results. J Pharm Pharmacol 2008; 60: 1019-28.
28. Ciardiello F, Bianco R, Caputo R et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004; 10: 784-93.
29. Chinnaiyan P, Huang S, Vallabhaneni G et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005; 65: 3328-35.
30. Harari PM, Huang SM. Modulation of molecular targets to enhance radiation. Clin Cancer Res 2000; 6: 323-5.
31. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res 2006; 12: 5268-72.
32. Baselga J, Cortes J. Epidermal growth factor receptor pathway inhibitors. Cancer Chemother Biol Response Modif 2005; 22: 205-23.
33. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7 (Suppl. 4): 2-8.
34. McIlwrath A, Vasey PA, Ross GM et al. Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-Type p53 for radiosensitivity. Cancer Res 1994; 54: 3718-22.
35. Williams JR, Zhang Y, Zhou H et al. Little, Genotype-dependent radiosensitivity: Clonogenic survival, apoptosis and cell-cycle redistribution. Int J Radiat Biol 2008; 84: 151-64.
36. Kaushal N, Bansal MP. Inhibition of CDC2/Cyclin B1 in response to selenium-induced oxidative stress during spermatogenesis: Potential role of Cdc25c and p21. Mol Cell Biochem 2007; 298: 139-50.
37. Mi Q, Kim S, Hwang BY et al. Silvestrol regulates G2/M checkpoint genes independent of p53 activity. Anticancer Res 2006; 26: 3349-56.
38. Chen YL, Lin SZ, Chang JY et al. In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells. Biochem Pharmacol 2006; 72: 308-19.
39. Chang KL, Kung ML, Chow NH et al. Genistein arrests hepatoma cells at G2/ M phase: Involvement of ATM activation and upregulation of p21waf1/cip1 and Wee1. Biochem Pharmacol 2004; 67: 717-26.
40. Ando T, Kawabe T, Ohara H et al. Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J Biol Chem 2001; 276: 42 971-7.
41. Iliakis G, Wang H, Perrault AR et al. Mechanisms of DNA double strand break repair and chromosome aberration formation. Cytogenet Genome Res 2004; 104: 14-20.
42. Gastaldo J, Viau M, Bencokova Z et al. Lead contamination results in late and slowly repairable DNA double-strand breaks and impacts upon the ATM-dependent signaling pathways. Toxicol Lett 2007; 173: 201-14.
43. Short SC, Bourne S, Martindale C et al. DNA damage responses at low radiation doses. Radiat Res 2005; 164: 292-302.
44. Chin C, Bae JH, Kim MJ et al. Radiosensitization by targeting radioresistance-related genes with protein kinase A inhibitor in radioresistant cancer cells. Exp Mol Med 2005; 37 (6): 608-18.
45. Carlomagno F, Burnet NG, Turesson I et al. Comparison of DNA repair protein expression and activities between human fibroblast cell lines with different radiosensitivities. Int J Cancer 2000; 85: 845-9.
46. Stea B, Falsey R, Kislin K et al. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa'). Cancer Lett 2003; 202: 43-51.
47. Andersson U, Johansson D, Behnam-Motlagh P et al. Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro. Acta Oncol 2007; 46: 951-60.